MSLN Antibody-Drug Conjugate With Protease-Cleavable Linker
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) targeting mesothelin (MSLN) face challenges such as high drug toxicity, a narrow therapeutic window, and low effective release of the drug in targeted organs, as well as interference from soluble MSLN which competes with membrane-anchored MSLN for antibody binding, reducing therapy efficacy.
Innovation Solution
Development of a novel antibody-drug conjugate (ADC) with a specific formulation that includes an antibody specifically binding to MSLN, linked to a biologically active molecule through a spacer unit, designed to enhance tumor-killing efficacy while minimizing systemic toxicity and interference from soluble MSLN.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional ADCs with non-degradable linkers are used, then the ADC can be manufactured with stable structure, but the drug toxicity is high and the therapeutic window is narrow
Solution Approach 1:
The patent changes the chemical parameter of the linker from non-degradable to degradable by specific proteases. The degradable linker contains peptide bonds that can be cleaved by proteases, transforming the linker's property from stable to conditionally labile, thereby reducing systemic toxicity while maintaining stability during circulation.
Solution Approach 2:
The degradable linker acts as an intermediary that mediates between the stable delivery requirement and the controlled drug release requirement. It remains intact during circulation (mediating stable delivery) but is cleaved by proteases at the target site (mediating controlled release), thus reducing off-target toxicity.
2Device complexity
If traditional ADCs are used, then the ADC structure is simple, but the effective release rate of the drug in targeted organs is low
Solution Approach 1:
The patent introduces dynamic characteristics to the ADC structure by incorporating a degradable linker that can transition from a stable state during circulation to a labile state upon protease cleavage. This dynamic property enables the linker to adapt its stability based on the biological environment, thereby improving drug release efficiency without significantly increasing structural complexity.
3Adaptability or versatility
If antibodies targeting MSLN are used, then the ADC can target MSLN-expressing tumors, but soluble MSLN competes with membrane-anchored MSLN for antibody binding, reducing therapy efficacy
Solution Approach 1:
The patent converts the harmful effect of soluble MSLN competition into a beneficial feature by designing an antibody with enhanced affinity and specificity for membrane-anchored MSLN. The antibody's engineered properties allow it to preferentially bind to the membrane-bound form even in the presence of soluble MSLN, thereby converting the competitive inhibition scenario into a selective targeting advantage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new ADC demonstrates improved anti-tumor efficacy, enhanced plasma stability, and reduced impact from soluble MSLN, leading to increased therapeutic effectiveness and safety in treating cancers with high MSLN expression.
Implementation Method 1
Ab is an antibody that specifically binds to mesothelin (MSLN) or an antigen-binding fragment
Implementation Method 2
linked to a biologically active molecule through a spacer unit
Data Source
Figure 1~2
Figure 3~4B
Figure 5~7
AI summary
Provided is an antibody-drug conjugate, which is a compound represented by formula (I) or a tautomer or a pharmaceutically acceptable salt thereof: Ab-[S-X-(Y)n-Z-E-D]q(I), wherein Ab is an antibody that specifically binds to mesothelin (MSLN) or an antigen-binding fragment thereof, and D is a bioactive molecular drug or a derivative thereof. Provided is a pharmaceutical composition, comprising the antibody-drug conjugate represented by formula (I). Provided is use of the antibody-drug conjugate represented by formula (I) and the pharmaceutical composition thereof in the preparation of a drug for treating cancer.